Trial results

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

NCT05813912 on ClinicalTrials.gov · last registry update 2026-06-03

A small phase 3 — 148 participants, against a typical 424. The sponsor logged completion for 14 April 2025. Primary outcome, as filed: Change in Glycated Haemoglobin (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

148

Started

2023-09-22

Primary completion

2025-04-14 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycated Haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.